All publications

Ethanol resistant extended release matrix tablets with Compritol® 888 ATO

• Poster

AAPS Annual Meeting and Exposition – San Diego (USA)  - Nov 2014

Yvonne Rosiaux, Jean-Michel Girard, Florence Desvignes, Cédric Miolane, Delphine Marchaud

Effect of Tablet Structure on Controlled Release from Supersaturating Solid Dispersions Containing Glyceryl Behenate.

• Scientific publication

Mol. Pharmaceutics, 2015, 12 (1), pp 120–126 DOI: 10.1021/mp500480y - Oct 2014

Justin M. Keen, Justin R. Hughey, Ryan C. Bennett, Vincent Jannin, Yvonne Rosiaux, Delphine Marchaud, and James W. McGinity

Estimating in vivo drug release from a new theophylline Compritol® 888 ATO matrix formulation using appropriate biorelevant test methods

• Poster

CRS Annual Meeting – Chicago (USA)  - Jul 2014

N. Fotaki, C. M. Long, Y. Rosiaux, D. Marchaud, Grzegorz Garbacz, S. Lange and S. Klein

Streamlining the design of sustained release matrix tablets using mathematical modeling for drug release optimization

• Poster

CRS Annual Meeting – Chicago (USA)  - Jul 2014

Y. Rosiaux, F. Desvignes, JM. Girard, C. Miolane, S. Hughes and D. Marchaud

Smart strategies for sustained release matrix tablets: Compritol® 888 ATO

• Whitepaper

OutsourcingPharma - May 2014

Gattefossé

This white paper gives an overview of how Compritol® 888 ATO provides clinically relevant sustained drug release profiles along with biopharmaceutical, formulation and manufacturing advantages.